ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

UCSF Receives $125 Million Gift for Cancer Hospital

March 27, 2009

Indoor Tanning Industry Funded Author Of NEJM Review On Vitamin D Deficiency.

April 18, 2008

New Treatment Approaches Valuable For Cancer Pain, Quality Of Life

September 27, 2002

New benchmark for CCSG award funding will be lowered from 20 percent of NCI research base to 15 percent, the program’s “reality ratio,” Karen Antman tells NCAB.

October 8, 2004

Neratinib Graduates from I-SPY Phase II Adaptive Trial Regimen

April 25, 2014

Drasga, Einhorn Make Appeal For Single-Payer Healthcare

January 31, 2014